Vyera Pharmaceuticals is developing therapies to treat patients suffering from serious and neglected diseases with unmet needs. Toxoplasmosis is such a disease.
Why Focus on Toxoplasmosis?
There has been no significant innovation in toxoplasmosis from the pharmaceutical industry in over 50 years.
Toxoplasmosis is considered a neglected parasitic infection that has been targeted as a priority for public health.
Vyera's discovery program identified novel drug candidates in hopes of creating a treatment that is more potent and better tolerated than existing options. One promising candidate has successfully undergone early-stage testing* and is awaiting additional support to proceed to the next level.
Vyera Facilitates Access to Our Products.
Vyera supports programs that offer financial assistance to patients in need and provides discounts to organizations that provide care to underserved patients.
*Hopper AT, Brockman A, Wise A, Gould J, Barks J, Radke JB, Sibley LD, Zou Y, Thomas S. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019 Feb 14;62(3):1562-1576.